Floatz logo

ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)

Chronic Myelogenous Leukemia (CML)

Gamida Cell ltdCell therapyPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

86 Active assets in the Chronic Myelogenous Leukemia (CML) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB

View all 50 →

Same molecule, other indications

ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF) is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →